FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation

Area of Science:

• Genetics and Molecular Biology
• Developmental Biology
• Cellular Signaling

Background:

• Fibroblast Growth Factor Receptor 3 (FGFR3) gene mutations are linked to skeletal dysplasias like achondroplasia.
• The functional mechanisms connecting FGFR3 mutations to disease severity remain unclear.
• Existing research suggests mutations lead to constitutively active receptors.

Purpose of the Study:

• To investigate the functional impact of various FGFR3 mutations, including the uncharacterized X807R mutation.
• To elucidate the relationship between FGFR3 mutation location and receptor activity.
• To understand how FGFR3 mutations affect receptor post-translational modifications and signaling.

Main Methods:

• Utilized a HEK cell culture model to examine different FGFR3 mutations.
• Analyzed receptor phosphorylation patterns in response to mutations.
• Assessed receptor glycosylation status and localization.
• Investigated downstream signaling events within the Golgi apparatus.

Main Results:

• Mutations in the intracellular domain of FGFR3 induced premature receptor phosphorylation.
• Intracellular domain mutations inhibited receptor glycosylation.
• Premature tyrosine phosphorylation of FGFR3 appears to inhibit its glycosylation.
• Mutations were associated with elevated receptor signaling in the Golgi apparatus.

Conclusions:

• Intracellular domain mutations in FGFR3 represent a distinct mechanism disrupting bone development.
• While a single factor doesn't correlate with pathological severity, intracellular mutations impact glycosylation and signaling.
• Further research is needed to fully understand the complex interplay between FGFR3 mutations and skeletal dysplasia pathogenesis.